ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc (XENE)

40.31
-1.32
(-3.17%)
Closed April 18 4:00PM
40.31
0.00
( 0.00% )
Pre Market: 4:09AM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
40.31
Bid
16.21
Ask
64.09
Volume
-
0.00 Day's Range 0.00
27.985 52 Week Range 50.99
Market Cap
Previous Close
40.31
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
363,883
Shares Outstanding
75,432,482
Dividend Yield
-
PE Ratio
-16.67
Earnings Per Share (EPS)
-2.42
Revenue
-
Net Profit
-182.39M

About Xenon Pharmaceuticals Inc

Founded in 1984, Xilinx is the leader in FPGAs by market share. Its chips are critical in the performance of various devices in the communications, data processing, industrial, consumer, and automotive markets. Founded in 1984, Xilinx is the leader in FPGAs by market share. Its chips are critical in the performance of various devices in the communications, data processing, industrial, consumer, and automotive markets.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Burnaby, British Columbia, Can
Founded
1970
Xenon Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker XENE. The last closing price for Xenon Pharmaceuticals was $40.31. Over the last year, Xenon Pharmaceuticals shares have traded in a share price range of $ 27.985 to $ 50.99.

Xenon Pharmaceuticals currently has 75,432,482 shares outstanding. The market capitalization of Xenon Pharmaceuticals is $3.04 billion. Xenon Pharmaceuticals has a price to earnings ratio (PE ratio) of -16.67.

XENE Latest News

Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting

VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced two oral presentations...

Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference

VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will...

Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days

VANCOUVER, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-2.36-5.5308179048542.6742.6739.5941255141.24607772CS
4-3.15-7.2480441785543.4644.46539.5931439542.11741428CS
12-4.8-10.640656173845.1150.9939.5936388345.54917078CS
265.2414.941545480535.0750.9927.98553447140.13437139CS
522.967.925033467237.3550.9927.98544987939.40583517CS
15620.61104.6192893419.750.9914.653555076933.42609626CS
26031.64364.936562868.6750.99739119830.23770678CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RWODRedwoods Acquisition Corporation
$ 17.74
(121.84%)
130.08k
ZCMDZhongchao Inc
$ 2.62
(80.69%)
1.48M
WLGSWang and Lee Group Inc
$ 0.758
(51.60%)
154.75k
HUBCHub Cyber Security Ltd
$ 1.64
(27.13%)
1.79M
RELIReliance Global Group Inc
$ 0.339
(23.23%)
3.31k
MBOTMicrobot Medical Inc
$ 0.36
(-59.55%)
4
BGLCBioNexus Gene Lab Corporation
$ 0.6121
(-27.87%)
26.97k
ISPCiSpecimen Inc
$ 0.34
(-19.24%)
70.25k
TIRXTian Ruixiang Holdings Ltd
$ 0.6521
(-18.49%)
76.13k
AGBAAGBA Group Holding Ltd
$ 0.88
(-14.56%)
223.04k
HUBCHub Cyber Security Ltd
$ 1.64
(27.13%)
1.79M
ZCMDZhongchao Inc
$ 2.62
(80.69%)
1.48M
SQQQProShares UltraPro Short QQQ
$ 12.40
(2.73%)
1.35M
SPCBSuperCom Ltd
$ 0.294
(22.50%)
1.05M
SINTSiNtx Technologies Inc
$ 0.0375
(-6.25%)
815.61k

XENE Discussion

View Posts
Monksdream Monksdream 3 months ago
XENE new 52 week high
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
MEAN XENE @ it aGAIN
πŸ‘οΈ0
LowFloatLopes LowFloatLopes 3 years ago
I bought some yesterday at close (26) hopefully I didn’t buy too high I never really buy while it’s up that much
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
$34 CLOSE= WOW


even after the Offering


XENE on radars))))))) tomorrow
πŸ‘οΈ0
rynlrt rynlrt 3 years ago
Don't really care about the semantics just the trade. Already up 1,000 on my Call
πŸ‘οΈ0
BottomBounce BottomBounce 3 years ago
$XENE Has $3.5M in debt
πŸ‘οΈ0
stock1ace1 stock1ace1 3 years ago
oh it will :D
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
WOW the $250M offering didnt really affect the pps


pretty impressive

πŸ‘οΈ0
stock1ace1 stock1ace1 3 years ago
Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $250 million of its common shares pursuant to its existing shelf registration statement. It is expected that the underwriters of the offering will be granted an option for a period of 30 days to purchase up to an additional $37.5 million of common shares at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
πŸ‘οΈ0
stock1ace1 stock1ace1 3 years ago
Offering β€”> Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $250 million of its common shares pursuant to its existing shelf registration statement. It is expected that the underwriters of the offering will be granted an option for a period of 30 days to purchase up to an additional $37.5 million of common shares at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
πŸ‘οΈ0
stock1ace1 stock1ace1 3 years ago
offering after hrs
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
$33'S WOW

XENE


I let my 6200 go too early
πŸ‘οΈ0
rynlrt rynlrt 3 years ago
If it breaks 30 it's gonna pop
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
Let's run the 30's >
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
YEHHHAAAAAAAA!
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
$30.47 new highs

XENE
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
William Blair Raises Price Target From $30 To $46; Raises Probability Of Success For XEN1101 In FOS From 60% To 85%

XENE
πŸ‘οΈ0
Marvy Marvy 3 years ago
500 shares to see where it goes
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
37M trading float >

XENE
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
MEAN XENE


πŸ‘οΈ0
make it happen make it happen 3 years ago
Not the flyest numbers. -83.4% Rev growth, -334.68% Operating margin

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -334.68%

Management Effectiveness
Return on Assets (ttm) -15.76%
Return on Equity (ttm) -26.46%

Income Statement
Revenue (ttm) 18.28M
Revenue Per Share (ttm) 0.48
Quarterly Revenue Growth (yoy) -83.40%
Gross Profit (ttm) -18.36M
EBITDA -60.38M
Net Income Avi to Common (ttm) -57.5M
πŸ‘οΈ0
make it happen make it happen 3 years ago
Good news but only phase 2. A long way to go still and will cost a lot of money to get there. Hemorrhaging almost $100,000,000 a hundred million a quarter.

Cash Flow Statement
Operating Cash Flow (ttm) -58.05M
Levered Free Cash Flow (ttm) -40.73M
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
30.24
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
Xenon Pharmaceuticals Reports Positive Phase 2b Result for Epilepsy Drug
7:21 am ET October 4, 2021 (Dow Jones) Print

By Matt Grossman


Xenon Pharmaceuticals Inc.'s XEN1101 drug achieved positive results in a Phase 2b trial studying its use as an adjunctive treatment for focal epilepsy, the company said Monday.

Compared with a placebo, the drug achieved a statistically significant reduction from the baseline in monthly focal seizure frequency, meeting the study's primary efficacy endpoint.

More than half of patients who received the highest dose of the medication studied experienced a greater-than-50% reduction in seizure frequency, Xenon said. At the median, participants had been experiencing a baseline level of 13.5 seizures per month before the study.

Xenon Chief Executive Ian Mortimer said that the results support an "attractive clinical profile" for the drug. Data from the study have also encouraged Xenon's plans to additionally develop the drug for the treatment of major depressive disorder and for other types of epilepsy, he said.


Write to Matt Grossman at matt.grossman@wsj.com


(END) Dow Jones Newswires

October 04, 2021 07:21 ET (11:21 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

XENE
πŸ‘οΈ0
diegonalesso diegonalesso 7 years ago
Insider trade alert, but low volumes
πŸ‘οΈ0
Klinsmann Klinsmann 7 years ago
On watch
πŸ‘οΈ0
Womack Womack 7 years ago
I mean I think you could play today for a quick rebound and flip it. I picked up 1k shares @4.80. See what happens. GL.
πŸ‘οΈ0
TheInvincibleBull TheInvincibleBull 7 years ago
$3.50-$3.75 should be a nice area to get shares imo for a nice flip?
πŸ‘οΈ0
Dr_Thorfin Dr_Thorfin 7 years ago
Xenon (NASDAQ:XENE) has bucked the downward trend in biotech this month and is up some 10% over the past few weeks. The stock also managed to rise nicely Friday even as the overall biotech sector gave up Thursday's gains. It sells for almost the exact price of Omeros as of the close of the trading week.
Since early August, three analyst firms have reiterated or initiated Buy ratings on this small biotech concern based in Canada. Price targets proffered range from $13 to $20 a share. Guggenheim is the most optimistic on Xenon with a $20 price target. Its analyst noted three reasons to be positive on the firm.
"1. XEN801 addresses an unmet need within the, large, ~$3.7B acne market and could present a novel mechanism of action to treat acne. The three mechanisms of action most commonly used to treat acne have been available for over 30 years. That said, innovative therapies launched over the past few decades have resulted in significant sales. This gives us confidence that XEN801 sales could exceed consensus expectations if it is approved.
2. The pain market needs safer drugs, outside of opioids, which XENE's Nav1.7 blockers could address. The government and the FDA's desire to reduce the abuse of opioids supports the development of novel pain drugs such as XENE's Nav1.7 blockers. We believe XENE and its partners for these drugs are well positioned to benefit from initiatives to move the market away from opioids.
3. There is a free call option on XENE's approved drug, Glybera, and other pipeline assets such as TV-45070 and Nav1.6, among others. Some of these assets could be monetized through partnerships"
Phase II readouts for XEN801 for the treatment of acne is due out inthe first quarter of 2017 and a Phase II readout for TV-45070 against Postherpetic neuralgia should hit in the first half of 2017. The company has just a $125 million market capitalization, positive analyst support and a couple of definable upcoming catalysts. One has to like Xenon's risk/reward profile over the next few quarters.
πŸ‘οΈ0
PharmaGreen007 PharmaGreen007 9 years ago
Well, this is absolutely amazing! Opened at $9 literally a couple of days ago and now we're trading over $16 a share.

πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock